SCHEMBL4776039

SCHEMBL4776039

CCOc1c(C)cccc1C1CC1C(=O)Nc1sc2c(c1C#N)CCNC2

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
NPC1 O15118 7/20 0.42
RAB9A P51151 7/20 0.42
ALDH1A1 P00352 6/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 2/20 0.39
POLB P06746 5/20 0.39
HPGD P15428 4/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
MAPK10 P53779 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771906 0.91 POLB (0.44) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4775000 0.91 ALDH1A1 (0.45) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4775272 0.88 POLB (0.43) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2895460 0.88 NPC1 (0.41) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4963439 0.88 ALDH1A1 (0.43) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4963443 0.87 ALDH1A1 (0.44) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4960897 0.86 ALDH1A1 (0.43) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4766038 0.85 POLB (0.48) MAPTNPC1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4962700 0.84 ALDH1A1 (0.43) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL4766163 0.84 RAB9A (0.41) MAPTNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893618-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-05 EP disclosed
WO-2006125815-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO disclosed